200 related articles for article (PubMed ID: 34491628)
1. In Silico Targeting Human Multidrug Transporter ABCG2 in Breast Cancer: Database Screening, Molecular Docking, and Molecular Dynamics Study.
Ibrahim MAA; Badr EAA; Abdelrahman AHM; Almansour NM; Mekhemer GAH; Shawky AM; Moustafa MF; Atia MAM
Mol Inform; 2022 Feb; 41(2):e2060039. PubMed ID: 34491628
[TBL] [Abstract][Full Text] [Related]
2. Prospective Drug Candidates as Human Multidrug Transporter ABCG2 Inhibitors: an In Silico Drug Discovery Study.
Ibrahim MAA; Badr EAA; Abdelrahman AHM; Almansour NM; Shawky AM; Mekhemer GAH; Alrumaihi F; Moustafa MF; Atia MAM
Cell Biochem Biophys; 2021 Jun; 79(2):189-200. PubMed ID: 33954893
[TBL] [Abstract][Full Text] [Related]
3. Naturally occurring plant-based anticancerous candidates as prospective ABCG2 inhibitors: an in silico drug discovery study.
Ibrahim MAA; Abdelrahman AHM; Badr EAA; Almansour NM; Alzahrani OR; Ahmed MN; Soliman MES; Naeem MA; Shawky AM; Sidhom PA; Mekhemer GAH; Atia MAM
Mol Divers; 2022 Dec; 26(6):3255-3277. PubMed ID: 35224675
[TBL] [Abstract][Full Text] [Related]
4. Structure-function relationships in ABCG2: insights from molecular dynamics simulations and molecular docking studies.
Ferreira RJ; Bonito CA; Cordeiro MNDS; Ferreira MU; Dos Santos DJVA
Sci Rep; 2017 Nov; 7(1):15534. PubMed ID: 29138424
[TBL] [Abstract][Full Text] [Related]
5.
Almansour NM; Abdelrahman AHM; Ismail Fagiree E; Ibrahim MAA
J Biomol Struct Dyn; 2023; 41(16):7651-7664. PubMed ID: 36120948
[TBL] [Abstract][Full Text] [Related]
6. A new porphyrin as selective substrate-based inhibitor of breast cancer resistance protein (BCRP/ABCG2).
Zattoni IF; Kronenberger T; Kita DH; Guanaes LD; Guimarães MM; de Oliveira Prado L; Ziasch M; Vesga LC; Gomes de Moraes Rego F; Picheth G; Gonçalves MB; Noseda MD; Ducatti DRB; Poso A; Robey RW; Ambudkar SV; Moure VR; Gonçalves AG; Valdameri G
Chem Biol Interact; 2022 Jan; 351():109718. PubMed ID: 34717915
[TBL] [Abstract][Full Text] [Related]
7. Designing of new tetrahydro-β-carboline-based ABCG2 inhibitors using 3D-QSAR, molecular docking, and DFT tools.
Ahmad S; Gupta D; Ahmed T; Islam A
J Biomol Struct Dyn; 2023; 41(23):14016-14027. PubMed ID: 36752362
[TBL] [Abstract][Full Text] [Related]
8. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
[TBL] [Abstract][Full Text] [Related]
9. Potential drug candidates as P-glycoprotein inhibitors to reverse multidrug resistance in cancer: an
Ibrahim MAA; Abdeljawaad KAA; Jaragh-Alhadad LA; Oraby HF; Atia MAM; Alzahrani OR; Mekhemer GAH; Moustafa MF; Shawky AM; Sidhom PA; Abdelrahman AHM
J Biomol Struct Dyn; 2023; 41(23):13977-13992. PubMed ID: 36883864
[TBL] [Abstract][Full Text] [Related]
10. Binding Site Interactions of Modulators of Breast Cancer Resistance Protein, Multidrug Resistance-Associated Protein 2, and P-Glycoprotein Activity.
Deng F; Ghemtio L; Grazhdankin E; Wipf P; Xhaard H; Kidron H
Mol Pharm; 2020 Jul; 17(7):2398-2410. PubMed ID: 32496785
[TBL] [Abstract][Full Text] [Related]
11. Derivative of 5-cyano-6-phenylpyrimidin antagonizes ABCB1- and ABCG2-mediated multidrug resistance.
Wang JQ; Wang B; Lei ZN; Teng QX; Li JY; Zhang W; Ji N; Cai CY; Ma LY; Liu HM; Chen ZS
Eur J Pharmacol; 2019 Nov; 863():172611. PubMed ID: 31476282
[TBL] [Abstract][Full Text] [Related]
12. The Selective Class IIa Histone Deacetylase Inhibitor TMP195 Resensitizes ABCB1- and ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs.
Wu CP; Lusvarghi S; Wang JC; Hsiao SH; Huang YH; Hung TH; Ambudkar SV
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905792
[TBL] [Abstract][Full Text] [Related]
13. Pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinolines: Novel compounds that reverse ABCG2-mediated resistance in cancer cells.
Karthikeyan C; Malla R; Ashby CR; Amawi H; Abbott KL; Moore J; Chen J; Balch C; Lee C; Flannery PC; Trivedi P; Faridi JS; Pondugula SR; Tiwari AK
Cancer Lett; 2016 Jun; 376(1):118-26. PubMed ID: 27012188
[TBL] [Abstract][Full Text] [Related]
14. Avapritinib: A Selective Inhibitor of KIT and PDGFRα that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines.
Wu CP; Lusvarghi S; Wang JC; Hsiao SH; Huang YH; Hung TH; Ambudkar SV
Mol Pharm; 2019 Jul; 16(7):3040-3052. PubMed ID: 31117741
[TBL] [Abstract][Full Text] [Related]
15. The Second-Generation PIM Kinase Inhibitor TP-3654 Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs.
Wu CP; Li YQ; Chi YC; Huang YH; Hung TH; Wu YS
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502348
[TBL] [Abstract][Full Text] [Related]
16. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel Plasmodium falciparum PI4KB inhibitors as potential anti-malarial drugs: Homology modeling, molecular docking and molecular dynamics simulations.
Ibrahim MAA; Abdelrahman AHM; Hassan AMA
Comput Biol Chem; 2019 Jun; 80():79-89. PubMed ID: 30928871
[TBL] [Abstract][Full Text] [Related]
18. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.
Gupta P; Zhang YK; Zhang XY; Wang YJ; Lu KW; Hall T; Peng R; Yang DH; Xie N; Chen ZS
Cell Physiol Biochem; 2018; 45(4):1515-1528. PubMed ID: 29486476
[TBL] [Abstract][Full Text] [Related]
19. Exploring Natural Product Activity and Species Source Candidates for Hunting ABCB1 Transporter Inhibitors: An In Silico Drug Discovery Study.
Ibrahim MAA; Abdeljawaad KAA; Abdelrahman AHM; Jaragh-Alhadad LA; Oraby HF; Elkaeed EB; Mekhemer GAH; Gabr GA; Shawky AM; Sidhom PA; Soliman MES; Moustafa MF; Paré PW; Hegazy MF
Molecules; 2022 May; 27(10):. PubMed ID: 35630581
[TBL] [Abstract][Full Text] [Related]
20. Optimization of the chromone scaffold through QSAR and docking studies: Identification of potent inhibitors of ABCG2.
Roussel E; Tran-Nguyen VK; Bouhedjar K; Dems MA; Belaidi A; Matougui B; Peres B; Azioune A; Renaudet O; Falson P; Boumendjel A
Eur J Med Chem; 2019 Dec; 184():111772. PubMed ID: 31630055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]